In this issue:
PARP inhibitor disruption of circadian rhythm linked to more frequent and severe toxicity
Best survival with treatment at high-volume centres with high NACT use
Could avutometinib + defactinib be a new standard of care for recurrent LGSOC?
VELIA fails to demonstrate a survival benefit to veliparib
Long-term disease control but no survival benefit to rucaparib maintenance
Is extensive cytoreductive surgery for stage 4 cancer justified?
Older women undergoing ovarian cancer surgery at risk for post-operative complications
SBRT promising for oligometastatic parenchymal lesions
Good outcomes with platinum rechallenge for early platinum-resistant relapse
Outcomes after interval and primary cytoreductive surgery in Australia
Please login below to download this issue (PDF)